Typbar Typhoid Conjugate Vaccine Current Affairs, GK & News
Bharat Biotech’s Typbar TCV, the world’s first clinically proven typhoid conjugate vaccine, has received pre-qualification from the World Health Organisation (WHO). It is the fourth generation vaccine against typhoid, proven to provide long-term protection to adults and infants – six months and older.
Pakistan becomes the first country to introduce WHO approved typhoid vaccine. The Vaccine is to be used in southern Sindh province as more than 10,000 cases of Typhoid were documented since 2017. Highlights A four-week campaign will be conducted targeting 10 million children of age nine months to 15 years. The campaign is launched with ..
Category: International Current Affairs
The World Health Organisation (WHO) has given its pre-qualification to Typbar Typhoid Conjugate Vaccine (TVC) developed by Hyderabad based Bharat Biotech for global use. Typbar TCV is world’s first typhoid vaccine clinically proven to be administered to children from six months of age to adults, and confers long-term protection against typhoid fever. It has been ..